(Q64907215)

30 June 2019

title

Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Eprosartan Study Group. (English)

1 reference

30 June 2019

author name string

Gradman AH

1

1 reference

30 June 2019

Gray J

2

1 reference

30 June 2019

Maggiacomo F

3

1 reference

30 June 2019

Punzi H

4

1 reference

30 June 2019

White WB

5

1 reference

30 June 2019

publication date

1 March 1999

1 reference

30 June 2019

published in

Clinical Therapeutics

1 reference

30 June 2019

volume

21

1 reference

30 June 2019

issue

3

1 reference

30 June 2019

page(s)

442-453

1 reference

30 June 2019

Do we need another antihypertensive agent?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

Goals of antihypertensive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

Angiotensin-converting enzyme inhibition and prostaglandins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

Clinical overview of irbesartan: a new angiotensin II receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

Compliance with antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2988300-9

7 January 2021

10.1016/S0149-2918(00)88300-9

Identifiers

DOI

1 reference

30 June 2019

1 reference

30 June 2019